Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-L1 Negative”

152 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 152 results

Testing effectiveness (Phase 2)Looking for participantsNCT04468061
What this trial is testing

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Who this might be right for
Breast CancerTriple Negative Breast CancerPD-L1 Negative
Dana-Farber Cancer Institute 110
Testing effectiveness (Phase 2)Ended earlyNCT03952325
What this trial is testing

Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC

Who this might be right for
Breast Cancer
Odonate Therapeutics, Inc. 294
Large-scale testing (Phase 3)Study completedNCT03197935
What this trial is testing

Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer

Who this might be right for
Triple-negative Breast Cancer
Hoffmann-La Roche 333
Early research (Phase 1)Ended earlyNCT02936102
What this trial is testing

FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Who this might be right for
Advanced Solid TumorsTriple Negative Breast CancerChordoma and Alveolar Soft Part Sarcoma
Novartis Pharmaceuticals 154
Testing effectiveness (Phase 2)Looking for participantsNCT06793553
What this trial is testing

Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC

Who this might be right for
Metastatic Breast Cancer
Japan Breast Cancer Research Group 106
Testing effectiveness (Phase 2)Looking for participantsNCT06963905
What this trial is testing

Saci Nivo Rela for TNBC

Who this might be right for
Metastatic Triple-negative Breast Cancer
Yale University 60
Testing effectiveness (Phase 2)Looking for participantsNCT04683679
What this trial is testing

Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

Who this might be right for
Triple Negative Breast CancerTNBC - Triple-Negative Breast CancerBreast Cancer+1 more
Memorial Sloan Kettering Cancer Center 34
Testing effectiveness (Phase 2)Study completedNCT03988036
What this trial is testing

A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)

Who this might be right for
Breast Cancer
Women's Cancer Study Group GmbH 46
Testing effectiveness (Phase 2)UnknownNCT05203276
What this trial is testing

Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC

Who this might be right for
Lung Neoplasms
The First People's Hospital of Lianyungang 40
Early research (Phase 1)Ended earlyNCT03292172
What this trial is testing

Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer

Who this might be right for
Advanced Ovarian CancerTriple Negative Breast Cancer
Hoffmann-La Roche 36
Early research (Phase 1)Looking for participantsNCT06022029
What this trial is testing

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

Who this might be right for
Triple Negative Breast CancerDiffuse Large B Cell LymphomaFollicular Lymphoma+11 more
OncoNano Medicine, Inc. 168
Testing effectiveness (Phase 2)Study completedNCT02530489
What this trial is testing

Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer

Who this might be right for
Breast AdenocarcinomaInvasive Breast CarcinomaTriple-Negative Breast Carcinoma
M.D. Anderson Cancer Center 37
Large-scale testing (Phase 3)Active Not RecruitingNCT06711900
What this trial is testing

SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 432
Testing effectiveness (Phase 2)Looking for participantsNCT03740893
What this trial is testing

PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer

Who this might be right for
Breast NeoplasmTriple Negative Breast Cancer (TNBC)HRD
Institute of Cancer Research, United Kingdom 119
Early research (Phase 1)Ended earlyNCT04060342
What this trial is testing

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Who this might be right for
Pancreatic AdenocarcinomaEsophageal AdenocarcinomaEsophageal Squamous Cell Carcinoma+11 more
GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. 61
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05859217
What this trial is testing

Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)

Who this might be right for
Lung CancerNSCLC Stage IVMetastatic NSCLC - Non-Small Cell Lung Cancer+1 more
Jun Zhang, MD, PhD 40
Large-scale testing (Phase 3)Study completedNCT04799249
What this trial is testing

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

Who this might be right for
TNBC - Triple-Negative Breast CancerBreast Cancer
G1 Therapeutics, Inc. 194
Large-scale testing (Phase 3)Active Not RecruitingNCT03833154
What this trial is testing

Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

Who this might be right for
Carcinoma, Non-Small-Cell Lung
AstraZeneca 724
Testing effectiveness (Phase 2)Ended earlyNCT04927884
What this trial is testing

Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies

Who this might be right for
Advanced Triple Negative Breast Cancer
ImmunityBio, Inc. 3
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07487519
What this trial is testing

Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.

Who this might be right for
Breast Cancer (Triple Negative Breast Cancer (TNBC))
Shanghai Henlius Biotech 180
Next Page